Peroxisome proliferator-activated receptor-γ: A versatile metabolic regulator

Annals of Medicine

Volumn 31, Issue 5, 1999, Pages 342-351

  Rocchi, Stéphane ^a   Auwerx, Johan ^a  

^a INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

Adipogenesis; Adipose tissue; Fatty acids; Gene expression; Insulin resistance; Nuclear receptors; Thiazolidinediones; Transcription; Type 2 diabetes

Indexed keywords

CELL NUCLEUS RECEPTOR; FATTY ACID DERIVATIVE; INSULIN; LIGAND; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PROSTAGLANDIN J2; THIAZOLIDINE DERIVATIVE;

ADIPOCYTE; ATHEROSCLEROSIS; CARCINOGENESIS; CELL CYCLE; CELL DIFFERENTIATION; DIABETIC OBESITY; GENE EXPRESSION REGULATION; HUMAN; INFLAMMATION; INSULIN SENSITIVITY; LIGAND BINDING; LIPID STORAGE; METABOLIC REGULATION; PRIORITY JOURNAL; REVIEW;

EID: 0032702272     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.3109/07853899908995901     Document Type: Review

References (107)

1. Spiegelman BM, Flier JS. Adipogenesis and obesity: rounding out the big picture. Cell 1996; 87: 377-89.
2. Schoonjans K, Marin G, Staels B, Auwerx J. Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr Opin Lipidol 1997; 8: 159-65.
3. Desvergne B, Wahli W. PPAR: a key nuclear factor in nutrient / gene interactions. In: Bauerle P, ed. Inducible Gene Expression. Vol 1. Boston: Birkhauser; 1994: 142-76.
4. Zhu Y, Qi C, Korenberg JR, Chen XN, Noya D, Rao MS, et al. Structural organization of mouse peroxisome proliferator activated receptor γ (mPPARγ) gene: alternative promoter use and different splicing yield two mPPARγ isoforms. Proc Natl Acad Sci U S A 1995; 92: 7921-5.
5. Fajas L, Auboeuf D, Raspe E, Schoonjans K, Lefebvre AM, Saladin R, et al. Organization, promoter analysis and expression of the human PPARγ gene. J Biol Chem 1997; 272: 18779-89.
6. Fajas L, Fruchart JC, Auwerx J. PPARγ3 mRNA: a distinct PPARγ mRNA subtype transcribed from an independent promoter. FEBS Lett 1998; 438: 55-60.
7. Schoonjans K, Staels B, Auwerx J. Role of the peroxisome proliferator activated receptor (PPAR) in mediating effects of fibrates and fatty acids on gene expression. J Lipid Res 1996; 37: 907-25.
8. Auboeuf D, Rieusset J, Fajas L, Vallier P, Frering V, Riou JP, et al. Tissue distribution and quantification of the expression of PPARs and LXRα in humans: no alterations in adipose tissue of obese and NIDDM patients. Diabetes 1997; 48: 1319-27.
9. Ricote M, Huang J, Fajas L, Li A, Welch J, Najib J, et al. Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci U S A 1998; 95: 7614-9.
10. Lefebvre AM, Laville M, Vega N, Riou JP, van Gaal L, Auwerx J, et al. Depot-specific differences in adipose tissue gene expression in lean and obese subjects. Diabetes 1998; 47: 98-103.
11. Rieusset J, Andreelli D, Auboeuf D, Roques M, Vallier P, Riou JP, et al. Insulin acutely regulates the expression of the peroxisome proliferator-activated receptor γ in human adipocytes. Diabetes 1999; 48: 699-705.
12. Vidal-Pulg AJ, Considine RV, Jimenez-Linan M, Werman A, Pories WJ, Caro JF, et al. Peroxisome proliferator-activated receptor gene expression in human tissues: effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest 1997; 99: 2416-22.
13. Xing H, Northrop JP, Grove JR, Kilpatrick KE, Su JL, Ringold GM. TNFα-mediated inhibition and reversal of adipocyte differentiation is accompanied by suppressed expression of PPARγ without effects on Pref-1 expression. Endocrinology 1997; 138: 2776-83.
14. Hill M, Young M, McCurdy C, Gimble J. Decreased expression of murine PPARγ in adipose tissue during endotoxinemia. Endocrinology 1997; 138: 3073-6.
15. Fajas L, Fruchart JC, Auwerx J. Transcriptional control of adipogenesis. Curr Opin Cell Biol 1998; 10: 165-73.
16. Yeh WC, Cao Z, Classon M, McKnight S. Cascade regulation of terminal adipocyte differentiation by three members of the C/EBP family of leucine zipper proteins. Genes Dev 1995; 9: 168-81.
17. Wu Z, Xie Y, Bucher NLR, Farmer SR. Conditional ectopic expression of C/EBPβ in NIH-3T3 cells induces PPARγ and stimulates adipogenesis. Genes Dev 1995; 9: 2350-63.
18. Wu Z, Bucher NLR, Farmer SR. Induction of peroxisome proliferator-activated receptor γ during the conversion of 3T3 fibroblasts into adipocytes is mediated by C/EBPβ, C/EBPδ, and glucocorticoids. Mol Cell Biol 1996; 16: 4128-36.
19. Wu Z, Rosen ED, Brun R, Hauser S, Adelmant G, Troy AE, et al. Cross-regulation of C/EBPα and PPARγ controls the transcriptional pathway of adipogenesis and insulin sensitivity. Mol Cell 1999; 3: 143-50.
20. Saladin R, Fajas L, Dana S, Halvorsen YD, Auwerx J, Briggs M. Differential regulation of peroxisome proliferator activated receptor γ1 (PPARγ1) and PPARγ2 mRNA expression in early stages of adipogenesis. Cell Growth Differ 1999; 10: 43-8.
21. DiRenzo J, Soderstrom M, Kurokawa R, Ogliastro MH, Ricote M, Ingray S, et al. Peroxisome proliferator-activated receptors and retinoic acid receptors differentially control the interactions of retinoid X receptor heterodimers with ligands, coactivators and corexpressors. Mol Cell Biol 1997; 17: 2166-76.
22. Xue JC, Schwarz EJ, Chawla A, Lazar MA. Distinct stages in adipogenesis revealed by retinoid inhibition of differentiation after induction of PPARγ. Mol Cell Biol 1996; 16: 1567-75.
23. Tontonoz P, Kim JB, Graves RA, Spiegelman BM. ADD1: a novel helix-loop-helix transcription factor associated with adipocyte determination and differentiation. Mol Cell Biol 1993; 13: 4753-9.
24. Kim JB, Spiegelman BM. ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism. Genes Dev 1996; 10: 1096-107.
25. Shimano H, Horton JD, Hammer RE, Shimomura I, Brown MS, Goldstein JL. Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a. J Clin Invest 1996; 98: 1575-84.
26. Lopez JM, Bennett MK, Sanchez HB, Rosenfeld JM, Osborne TF. Sterol regulation of acetyl coenzyme A carboxylase: a mechanism for coordinate control of cellular lipid. Proc Natl Acad Sci U S A 1996; 93: 1049-53.
27. Bennet MK, Lopez JM, Sanchez HB, Osborne TF. Sterol regulation of fatty acid synthase promoter: coordinate feedback regulation of two major lipid pathways. J Biol Chem 1995; 270: 25578-83.
28. Kim JB, Wright HM, Wright M, Spiegelman BM. ADD1/ SREBP1 activates PPARγ through the production of endogeneous ligand. Proc Natl Acad Sci U S A 1998; 95: 4333-7.
29. Fajas L, Schoonjans K, Gelman L, Kim JB, Najib J, Martin G, et al. Regulation of PPARγ expression by ADD1/SREBP-1: implications for adipocyte differentiation and metabolism. Mol Cell Biol 1999; 19: 5495-503.
30. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell 1994; 79: 1147-56.
31. Hu E, Tontonoz P, Spiegelman BM. Transdifferentiation of myoblasts by the adipogenic transcription factors PPARγ and C/EBPα. Proc Natl Acad Sci U S A 1995; 92: 9856-60.
32. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM. mPPARy2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 1994; 8: 1224-34.
33. Tontonoz P, Hu E, Devine J, Beale EG, Spiegelman BM. PPARγ2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene. Mol Cell Biol 1995; 15: 351-7.
34. Schoonjans K, Staels B, Grimaldi P, Auwerx J. Acyl-CoA synthetase mRNA expression is controlled by fibric-acid derivatives, feeding and liver proliferation. Eur J Biochem 1993; 216: 615-22.
35. Schoonjans K, Watanabe M, Suzaki H, Mahfoudi A, Krey G, Wahli W, et al. Induction of the acyl-coenzyme A synthetase gene by fibrates and fatty acids is mediated by a peroxisome proliferator response element in the C promoter. J Biol Chem 1995; 270: 19269-76.
36. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM. PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 1998; 93: 241-52.
37. Martin G, Schoonjans K, Lefebvre A, Staels B, Auwerx J. Coordinate regulation of the expression of the fatty acid transport protein (FATP) and acyl CoA synthetase genes by PPARα and PPARγ activators. J Biol Chem 1997; 272: 28210-7.
38. Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, Heyman RA, Briggs M, Deeb S, et al. PPARα and PPARγ activators direct a tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J 1996; 15: 5336-48.
39. Hui TY, Frohnert BI, Smith AJ, Schaffer JE, Bernlohr DA. Characterization of the murine fatty acid transport protein gene and its insulin response sequence. J Biol Chem 1998; 273: 27420-9.
40. Schoonjans K, Martin G, Staels B, Auwerx J. Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr Opin Lipidol 1997; 8: 159-66.
41. Auwerx J, Staels B. Leptin. Lancet 1998; 351: 737-42.
42. De Vos P, Lefebvre AM, Miller SG, Guerro-Millo M, Wong K, Saladin R, et al. Thiazolidinediones repress ob gene expression via activation of PPARγ. J Clin Invest 1996; 98: 1004-9.
43. Zhang B, Graziano MP, Doebber TW, Leibwitz MD, White-Carrington S, Szalkowski DM, et al. Down-regulation of the expression of the obese gene by antidiabetic thiazolidinedione in Zucker diabetic fatty rats and db/db mice. J Biol Chem 1996; 271: 9455-9.
44. Kallen CB, Lazar MA. Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes. Proc Natl Acad Sci U S A 1996; 93: 5793-6.
45. Miller SG, De Vos P, Guerre-Millo M, Wong K, Hermann T, Staels B, et al. The adipocyte specific transcription factor, C/ EBPα modulates human ob gene expression. Proc Natl Acad Sci U S A 1996; 93: 5507-11.
46. He Y, Chen H, Quon MJ, Reitman M. The mouse obese gene. Genomic organization, promoter activity, and activation by CCAAT/enhancer-binding protein alpha. J Biol Chem 1995; 270: 28887-91.
47. Hollenberg AN, Susulic VS, Madura JP, Zhang B, Moller DE, Tontonoz P, et al. Functional antagonism between CCAAT/Enhancer binding protein-α and peroxisome proliferator-activated receptor-γ on the leptin promoter. J Biol Chem 1997; 272: 5283-90.
48. Torti FM, Dieckman B, Beutler B, Cerami A, Ringold GM. A macrophage factor inhibits adipocyte gene expression: an in vitro model for cachexia. Science 1985; 229: 867-9.
49. Beutler B, Cerami A. Cachectin (tumor necrosis factor): a macrophage hormone governing cellular metabolism and inflammatory response. Endocrine Rev 1988; 9: 57-66.
50. Williams PM, Chang DJ, Danesch U, Ringold GM, Heller RA. CCAAT/enhancer binding protein expression is rapidly extinguished in TA1 adipocyte cells treated with tumor necrosis factor. Mol Endocrinol 1992; 6: 1135-41.
51. Ron D, Brasier AR, McGehee REJ, Habener JF. Tumor necrosis factor-induced reversal of adipocytic phenotype of 3T3-L1 cells is preceded by a loss of nuclear CCAAT/ enhancer binding protein (C/EBP). J Clin Invest 1992; 89: 223-33.
52. Peraldi P, Xu M, Spiegelman BM. Thiazolidinediones block tumor necrosis factor-α-induced inhibition of insulin signalling. J Clin Invest 1997; 100: 1863-9.
53. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose tissue expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91.
54. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J Clin Invest 1995; 95: 2409-15.
55. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α and obesity induced insulin resistance. Science 1996; 271: 665-8.
56. Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM. Tumor necrosis factor α inhibits signaling from the insulin receptor. Proc Natl Acad Sci U S A 1994; 91: 4854-8.
57. Shao D, Lazar MA. Peroxisome proliferator activated receptor γ, CCAAT/enhancer binding protein α and cell cycle status regulate the commitment to adipocyte differentiation. J Biol Chem 1997; 272: 21473-8.
58. Hofmann C, Lorenz K, Braithwaite SS, Colca JR, Palazuk BJ, Hotamisligil GS, et al. Altered gene expression for tumor necrosis factor-α and its receptor during drug and dietary modulation of insulin resistance. Endocrinology 1994; 134: 264-70.
59. Okuno A, Tamemoto H, Tobe K, Veki K, Mori Y, Iwamoto K, et al. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 1998; 101: 1354-61.
60. Cohen B, Novick D, Rubinstein M. Modulation of insulin activities by leptin. Science 1996; 274: 1185-8.
61. Muller G, Ertl J, Gerl M, Preibisch G. Leptin impairs metabolic actions of insulin in isolated rat adipocytes. J Biol Chem 1997; 272: 10585-93.
62. Liu YL, Emilsson V, Cawthorne MA. Leptin inhibits glycogen synthesis in isolated soleus muscle of obese (ob/ob) mice. FEBS Lett 1997; 411: 351-5.
63. Martin G, Schoonjans K, Staels B, Auwerx J. PPARγ activators improve glucose homeostasis by stimulating fatty acid uptake in the adipocytes. Atherosclerosis 1998; 137: 75-80.
64. Oakes ND, Camilleri S, Furler SM, Chisholm DJ, Kraegen EW. The insulin sensitizer, BRL 49653, reduces systemic fatty acid supply and utilization and tissue availability in the rat. Metabolism 1997; 46: 935-42.
65. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose-fatty acid cycle: its role in insulin sensitivity and metabolic disturbances of diabetes mellitus. Lancet 1961; I: 785-9.
66. Moller DE, Flier JS. Insulin resistance: mechanisms, syndromes, and implications. N Engl J Med 1991; 325: 938-48.
67. Shimomura I, Hammer RE, Richardson JA, Ikemoto S, Bashmakov Y, Goldstein JL, et al. Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: a model for congenital generalized lipodystrophy. Genes Dev 1998; 12: 3182-94.
68. Moitra J, Mason MM, Olive M, Krylov D, Gavrilova O, Marcus-Samuels B, et al. Life without fat: a transgenic mouse. Genes Dev 1998; 12: 3168-81.
69. Burant CF, Sreenan S, Hirano K-I, Tai TA, Lohmiller J, Lukens J, et al. Troglitazone action is independent of adipose tissue. J Clin Invest 1997; 100: 2900-8.
70. Gelman L, Fruchart J-C, Auwerx J. An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer. Cell Mol Life Sci 1999; 55: 932-43.
71. Wu Z, Xie Y, Morrison RF, Bucher NLR, Farmer SR. PPARγ induces the insulin dependent glucose transporter GLUT4 in absence of C/EBPα during the conversion of 3T3 fibroblast into adipocytes. J Clin Invest 1998; 101: 22-32.
72. Ribon V, Johnson JH, Camp HS, Saltiel AR. Thiazolidinediones and insulin resistance: peroxisome proliferator-activated receptor γ activation stimulates expression of the CAP gene. Proc Natl Acad Sci U S A 1998; 95: 14751-6.
73. Bouchard C, Perusse L. Genetics of obesity. Annu Rev Nutr 1993; 13: 337-54.
74. Whitaker RC, Wright JA, Pepe MS, Seidel KD, Dietz WH. Predicting obesity in young adulthood from childhood and parental obesity. N Engl J Med 1997; 337: 869-73.
75. Vigouroux C, Fajas L, Khallouf E, Meier M, Gyapay G, Lascols O, et al. Human peroxisome proliferator-activated receptor-gamma2: genetic mapping, identification of a variant in the coding sequence, and exclusion as the gene responsible for lipoatrophic diabetes. Diabetes 1998; 47: 490-2.
76. Ristow M, Muller-Wieland D, Pfeiffer A, Krone W, Kahn CR. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. N Engl J Med 1998; 339: 953-9.
77. Yen CJ, Beamer BA, Negri C, Silver K, Brown KA, Yarnall DP, et al. Molecular scanning of the human peroxisome proliferator activated receptor gamma gene in diabetic Caucasians: identification of a Prol2Ala PPARgamma 2 missense mutation. Biochem Biophys Res Commun 1997; 241: 270-4.
78. Deeb S, Fajas L, Nemoto M, Laakso M, Fujimoto W, Auwerx J. A Pro 12 Ala substitution in the human peroxisome proliferator-activated receptor gamma2 is associated with decreased receptor activity, improved insulin sensitivity, and lowered body mass index. Nat Genet 1998; 20: 284-7.
79. Beamer BA, Yen CJ, Andersen RE, Muller D, Elahi D, Cheskin LJ, et al. Association of the Prol2Ala variant in peroxisome proliferator-activated receptor gamma2 gene with obesity in two Caucasian populations. Diabetes 1998; 47: 1806-8.
80. Mori Y, Kim-Motoyama H, Katakura T, Yasuda K, Kadowaki H, Beamer BA, et al. Effect of the Prol2Ala variant of the human peroxisome proliferator activated receptor γ2 gene on adiposity, fat distribution, and insulin sensitivity in Japanese men. Biochem Biophys Res Commun 1998; 251: 195-8.
81. Ek J, Urhammer SA, Sorensen TIA, Andersen T, Auwerx J, Pedersen O. Homozygosity of the Prol2Ala variant of the peroxisome proliferator activated receptor γ2 (PPARγ2): divergent modulating effects on body mass index in obese and lean men of Caucasian origin. Diabetologia 1999; 42: 892-5.
82. Werman A, Hollenberg A, Solanes G, Bjorbaek C, Vidal-Pulg A, Flier JS. Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor γ (PPARγ). Differential activity of PPAR γ1 and -2 isoforms and influence of insulin. J Biol Chem 1997; 272: 20230-5.
83. Gelman L, Zhou G, Fajas L, Raspe E, Fruchart JC, Auwerx J. p300 interacts with the N- and C-terminal part of PPARγ2 in a ligand-independent and -dependent manner, respectively. J Biol Chem 1999; 274: 7681-8.
84. Shao D, Rangwala SM, Bailey ST, Krakow SL, Reginato MJ, Lazar MA. Interdomain communication regulating ligand binding by PPAR gamma. Nature 1998; 396: 377-80.
85. Serhan CN, Haeggstrom JZ, Leslie CC. Lipid mediator networks in cell signaling: update and impact of cytokines. FASEB J 1996; 10: 1147-58.
86. Jiang C, Ting AT, Seed B. PPARγ agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391: 82-6.
87. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor γ is a negative regulator of macrophage activation. Nature 1998; 391: 79-82.
88. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA. Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1997; 272: 3406-10.
89. Greene ME, Blumberg B, McBride OW, Yi HF, Kronquist K, Kwan K, et al. Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping. Gene Expression 1995; 4: 281-99.
90. Nagy L, Tontonez P, Alvarez JG, Chen H, Evans RM. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ. Cell 1998; 93: 229-40.
91. Marx N, Sukhova G, Murphy C, Libby P, Plutzky J. Macrophages in human atheroma contain PPARgamma: differentiation-dependent PPARgamma expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. Am J Pathol 1998; 153: 17-23.
92. Marx N, Schoenbeck U, Lazar MA, Libby P, Plutzky J. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res 1998; 83: 1097-103.
93. Spiegelman BM. PPARgamma in monocytes: less pain, any gain? Cell 1998; 93: 153-5.
94. Altiek S, Xu M, Spiegelman B. PPARγ induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A. Genes Dev 1997; 11: 1987-98.
95. Hansen JB, Petersen RK, Larsen BM, Bartkova J, Alsner J, Kristiansen K. Activation of peroxisome proliferator activated receptor γ bypasses the function of the retinoblastoma protein in adipocyte differentiation. J Biol Chem 1999; 274: 2386-93.
96. Tontonoz P, Singer S, Forman BM, Sarraf P, Fletcher JA, Fletcher DC, et al. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc Natl Acad Sci U S A 1997; 94: 237-41.
97. Elstner E, Muller C, Koshizuka K, Williamson EA, Park D, Asou H, et al. Ligands for peroxisome proliferator-activated receptor γ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci U S A 1998; 95: 8806-11.
98. Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, et al. Terminal differentiation of human breast cancer through PPARγ. Mol Cell 1998; 1: 465-70.
99. Brockman JA, Gupta RA, DuBois RN. Activation of PPARγ leads to inhibition of anchorage-independent growth of human colorectal cancer cells. Gastroenterology 1998; 115: 1049-55.
100. Kubota T, Koshizaka K, Williamson EA, Asou H, Said JW, Holden S, et al. Ligand for peroxisome proliferator activated receptor γ (troglitazone) has potent anti-tumor effects against human prostate cancer both in vitro and in vivo. Cancer Res 1998; 58: 3344-52.
101. Min /+ mice. Nat Med 1998; 4: 1053-7.
102. Saez E, Tontonoz P, Nelson MC, Alvarez JG, Ming UT, Baird SM, et al. Activators of the nuclear receptor PPARγ enhance colon polyp formation. Nat Med 1998; 4: 1058-61.
103. Kinzler KW, Vogelstein B. Lessons from heriditary colorectal cancer. Cell 1996; 87: 159-70.
104. Mansen A, Guardiola-Diaz H, Rafter J, Branting C, Gustafsson JA. Expression of the peroxisome proliferator-activated receptor (PPAR) in the mouse colonie mucosa. Biochem Biophys Res Commun 1996; 222: 844-51.
105. Giovanucci E, Willet WC. Dietary factors and risk of colon cancer. Ann Med 1994; 26: 443-52.
106. Wasan HS, Novelli M, Bee J, Bodmer WF. Dietary fat influences on polyp phenotype in multiple intestinal neoplasia mice. Proc Natl Acad Sci U S A 1997; 94: 3308-13.
107. Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, et al. Differentiation and reversal of malignant changes in colon cancer through PPARγ. Nat Med 1998; 4: 1046-52.